The cardiovascular risk of JAK inhibitors in treating rheumatic diseases.

This document summarizes a study on the cardiovascular risks of Janus kinase inhibitors (JAKi) in patients with rheumatic diseases. The study found that the impact of JAKi on cardiovascular risk is complex and may vary depending on factors such as baseline risk factors, disease activity, and type of rheumatic disease. Some studies suggest an increased cardiovascular risk with JAKi, especially in older patients with risk factors, while others found no significant difference compared to other treatments. More research is needed to fully understand the relationship between JAKi and cardiovascular risk. [Extracted from the article]